Bachem presents latest custom peptide synthesis offers to CPhI Chicago
News | Bachem AG
APRIL 23, 2019
Bubendorf, Switzerland: – Peptide technology specialist Bachem AG will be a leading exhibitor at the upcoming CPhI North America expo in Chicago.
This is a return to CPhI North America for Bachem, who will exhibit from Stand 2349 Chicago’s McCormick Center.
Custom peptide synthesis
The Bachem display will feature the company’s wide range of CMO offers in off-the-shelf biochemicals and research and production-focused custom synthesis services for research labs and pharma and biotech industries, presented under its banner of ‘Pioneering Partner for Peptides’.
It will also highlight latest developments, such as the ISO 13485 certification of its production site in St. Helens, UK and the introduction of the Bachem custom synthesis service that accelerates the production of specifically targeted peptides from milligram up to kilogram scale.
Small molecule expertise
The Bachem stand will also focus on its innovative portfolio of small molecule APIs and proprietary processes that harness its outstanding knowledge of peptide and carbohydrate chemistry.
Over recent months, Bachem’s award-winning single glycosylation process enabled production scale chemical synthesis of Interferon β-1a, along with custom manufacturing, synthetic organic chemistry, generic peptidic and small molecule APIs.
The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.
Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).
A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics and new chemical entities (NCEs).
About CPhI North America
CPhI North America made its debut in 2017 as a new development of the highly successful CPhI worldwide franchise first established in 1989. Originally conceived as a chemical and pharmaceutical ingredients show, CPhI is now a global series of events for the whole pharmaceutical value chain, taking in events all over the world attracting more than 100,000 attendees annually.
The fourth CPhI North America Expo is a three-day event opening April 30, 2019, at the McCormick Centre in Chicago. It brings together seven shows in one, co-locating CPhI Connect for pharmaceutical ingredients with six other zones, including Informex (fine and specialty chemicals), iCSE (drugs development) FDF (finished drug products), P-Mec (Machinery), and InnoPack for packaging.
The conference is powered by three tracks of programming covering Drug Development, Drug Manufacturing and Bio-Processing.
CPhI North America is staged by leading Global B2B events organizer and publisher UBM Live, with more information at: https://cphinorthamerica.com/.
Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107
Click on Bachem at CPhI NA 2019 for more information.
Click on Bachem to contact the company directly.
Click on Bachem Custom Synthesis to learn more.
Click on Chemical Glycosylation of Peptides to download brochure.